Trial Profile

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etakafusp alfa (Primary) ; Ramucirumab (Primary) ; Rilvegostomig (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ALTAIR
Sponsors AstraZeneca

Most Recent Events

02 Mar 2026 According to Compugen Ltd media release, further clinical data anticipated from this trail is expected in this year.
19 Dec 2025 Planned number of patients changed from 182 to 152.
19 Dec 2025 Planned End Date changed from 13 Oct 2028 to 23 Feb 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com